Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tezacitabine + oxaliplatin
- Development stage
- Discontinued
- Lead developer
- Manufacturer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tezacitabine + oxaliplatin is an investigational combination therapy comprising tezacitabine, a nucleoside analog, and oxaliplatin, a platinum-based chemotherapeutic agent. Tezacitabine acts by inhibiting DNA synthesis through incorporation into DNA, leading to chain termination and apoptosis. Oxaliplatin forms DNA crosslinks primarily at guanine bases, causing DNA double-strand breaks and triggering apoptosis. This combination has been studied in clinical trials for the treatment of metastatic colorectal cancer, aiming to leverage the synergistic cytotoxic effects of both agents to improve antitumor efficacy[3][5].
- Other names
- Tezacitabine and oxaliplatinTezacitabine/oxaliplatin
02
Targets
DNA
Beyond the preview
Go deeper on tezacitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tezacitabine + oxaliplatin.